La malattia di Fabry oggi

La malattia di Fabry oggi Fabry disease is a multisystemic, X-linked recessive lysosomal storage disease caused by decreased activity of alpha-galactosidase A that results in lysosomal accumulations of the glycosphingolipid GL-3. Progressive glycolipid accumulation is initially reversible but leads with time to tissue damage and later to organ failure in the third to the fourth decade and early death. It is an underdiagnosed condition leading to a delayed start of therapies and consequently to a lack of efficacy.Several aspects of the disease have been clarified by research but there still remains much to learn about specific issues. Practitioners should highly suspect Fabry disease in individuals presenting with the signs and symptoms mentioned above, along with the information gleaned from a thorough personal and family history and physical examination. Great effort has been made by screening studies, which should be extended to all the risk categories. The pathogenetic role of new mutations should be investigated. Preliminary studies have shown enzyme replacement therapy and chaperone therapy to be effective when started early. However, new therapies are coming on the horizon and this bodes well for the future of patients suffering from Fabry disease. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Giornale di Techniche Nefrologiche e Dialitiche SAGE

La malattia di Fabry oggi

Loading next page...
 
/lp/sage/la-malattia-di-fabry-oggi-ZAnMH3naud
Publisher
SAGE
Copyright
© The Author(s) 2018
ISSN
0394-9362
eISSN
1724-5974
D.O.I.
10.1177/0394936218760839
Publisher site
See Article on Publisher Site

Abstract

Fabry disease is a multisystemic, X-linked recessive lysosomal storage disease caused by decreased activity of alpha-galactosidase A that results in lysosomal accumulations of the glycosphingolipid GL-3. Progressive glycolipid accumulation is initially reversible but leads with time to tissue damage and later to organ failure in the third to the fourth decade and early death. It is an underdiagnosed condition leading to a delayed start of therapies and consequently to a lack of efficacy.Several aspects of the disease have been clarified by research but there still remains much to learn about specific issues. Practitioners should highly suspect Fabry disease in individuals presenting with the signs and symptoms mentioned above, along with the information gleaned from a thorough personal and family history and physical examination. Great effort has been made by screening studies, which should be extended to all the risk categories. The pathogenetic role of new mutations should be investigated. Preliminary studies have shown enzyme replacement therapy and chaperone therapy to be effective when started early. However, new therapies are coming on the horizon and this bodes well for the future of patients suffering from Fabry disease.

Journal

Giornale di Techniche Nefrologiche e DialiticheSAGE

Published: Mar 1, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off